KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Notes Payables: 2016-2017

Historic Notes Payables for Vertex Pharmaceuticals (VRTX) over the last 1 years, with Dec 2017 value amounting to $232.4 million.

  • Vertex Pharmaceuticals' Notes Payables rose 216.55% to $232.4 million in Q4 2017 from the same period last year, while for Dec 2017 it was $232.4 million, marking a year-over-year increase of 216.55%. This contributed to the annual value of $232.4 million for FY2017, which is 216.55% up from last year.
  • Per Vertex Pharmaceuticals' latest filing, its Notes Payables stood at $232.4 million for Q4 2017, which was up 22.14% from $190.3 million recorded in Q3 2017.
  • Vertex Pharmaceuticals' Notes Payables' 5-year high stood at $232.4 million during Q4 2017, with a 5-year trough of $73.4 million in Q4 2016.
  • Moreover, its 2-year median value for Notes Payables was $147.7 million (2017), whereas its average is $149.7 million.
  • Data for Vertex Pharmaceuticals' Notes Payables shows a peak YoY skyrocketed of 216.55% (in 2017) over the last 5 years.
  • Vertex Pharmaceuticals' Notes Payables (Quarterly) stood at $73.4 million in 2016, then spiked by 216.55% to $232.4 million in 2017.
  • Its last three reported values are $232.4 million in Q4 2017, $190.3 million for Q3 2017, and $147.7 million during Q2 2017.